Luye Pharma Group Ltd. (HK:2186)
:2186
Want to see HK:2186 full AI Analyst Report?
2186 Stock Chart & Stats
HK$3.02
HK$0.04(1.95%)
At close: 4:00 PM EST
HK$3.02
HK$0.04(1.95%)
Day’s Range― - ―
52-Week RangeHK$2.03 - HK$4.49
Previous CloseN/A
Volume7.60M
Average Volume (3M)38.67M
Market Cap
HK$8.84B
Enterprise ValueHK$12.76B
Total Cash (Recent Filing)HK$8.88B
Total Debt (Recent Filing)HK$9.42B
Price to Earnings (P/E)8.3
Beta0.86
Next Earnings
Aug 27, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.16
Shares Outstanding3,994,515,900
10 Day Avg. Volume34,399,920
30 Day Avg. Volume38,673,367
Financial Highlights & Ratios
PEG Ratio0.67
Price to Book (P/B)0.60
Price to Sales (P/S)1.52
P/FCF Ratio12.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$4.32Price Target Upside43.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.17
Revenue Forecast (FY)HK$6.95B
Bulls Say, Bears Say
Bulls Say
High Profit MarginsSustained high gross and EBITDA margins indicate durable pricing power and efficient production for branded drugs. That margin buffer supports investment in R&D and commercialization, helping the firm absorb revenue volatility while maintaining operating cash generation over the medium term.
Improving Leverage And Balance SheetMaterial reduction in leverage restores financial flexibility and reduces interest burden, enabling more stable funding for drug development and go-to-market activities. A stronger balance sheet lowers refinancing risk and supports capital allocation for strategic initiatives over the coming months.
Rebound In Operating Cash Flow And Positive FCFThe recovery to positive operating and free cash flow demonstrates the company's ability to convert earnings into cash after a weak prior year. Improved cash generation enhances internal funding for R&D, manufacturing capacity and reduces near-term reliance on external financing.
Bears Say
Sharp Revenue DeclineA ~37% revenue drop in 2025 signals meaningful demand weakness or product lifecycle setbacks. Such a large top-line contraction threatens long-term margin sustainability and raises questions about product mix, market access or loss of key revenue streams unless new growth drivers are established.
Historically Volatile Free Cash FlowRepeated swings in free cash flow reduce predictability for capex, R&D spending and dividends. Volatility increases the need for precautionary liquidity or external funding, complicating long-term planning and potentially constraining strategic investments during weaker cycles.
Low Return On EquityA ROE near 3.7% implies the enlarged equity base isn't translating into strong shareholder returns. This suggests capital deployment has limited effectiveness and could pressure investor confidence and limit ability to attract equity funding for expansion without operational improvements.
Luye Pharma Group News
2186 FAQ
What was Luye Pharma Group Ltd.’s price range in the past 12 months?
Luye Pharma Group Ltd. lowest stock price was HK$2.03 and its highest was HK$4.49 in the past 12 months.
What is Luye Pharma Group Ltd.’s market cap?
Luye Pharma Group Ltd.’s market cap is HK$8.84B.
When is Luye Pharma Group Ltd.’s upcoming earnings report date?
Luye Pharma Group Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 98 days.
How were Luye Pharma Group Ltd.’s earnings last quarter?
Luye Pharma Group Ltd. released its earnings results on Mar 30, 2026. The company reported HK$0.092 earnings per share for the quarter, the consensus estimate of HK$0.092 by HK$0.
Is Luye Pharma Group Ltd. overvalued?
According to Wall Street analysts Luye Pharma Group Ltd.’s price is currently Undervalued.
Does Luye Pharma Group Ltd. pay dividends?
Luye Pharma Group Ltd. pays a Annually dividend of HK$0.06 which represents an annual dividend yield of N/A. See more information on Luye Pharma Group Ltd. dividends here
What is Luye Pharma Group Ltd.’s EPS estimate?
Luye Pharma Group Ltd.’s EPS estimate is 0.06.
How many shares outstanding does Luye Pharma Group Ltd. have?
Luye Pharma Group Ltd. has 3,994,515,900 shares outstanding.
What happened to Luye Pharma Group Ltd.’s price movement after its last earnings report?
Luye Pharma Group Ltd. reported an EPS of HK$0.092 in its last earnings report, expectations of HK$0.092. Following the earnings report the stock price went up 3.719%.
Which hedge fund is a major shareholder of Luye Pharma Group Ltd.?
Currently, no hedge funds are holding shares in HK:2186
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Luye Pharma Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$4.32 (43.05% Upside)
HK$4.32 (43.05% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-31.45%
12-Months-Change
Fundamentals
Return on Equity
3.99%
Trailing 12-Months
Asset Growth
15.79%
Trailing 12-Months
Company Description
Luye Pharma Group Ltd.
Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian and breast cancer; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers and other solid tumors; and Xuezhikang, a lipid regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; Rivastigmine Transdermal Patch for the treatment of Alzheimer's disease; Fentanyl Transdermal Patch for cancer pain; Buprenorphine Transdermal Patch for chronic pain; and Seroquel and Seroquel XR for the treatment of schizophrenia and manic episodes of bipolar affective disorders, In addition, the company offers Rykindo, an injection for the treatment of schizophrenia; Tiandixin used as an adjuvant therapy for malignant tumors, hydrothorax and ascites, and respiratory infections; Yitaida for acute promyelocytic leukemia and liver cancer; Lutingnuo, a glutathione injection for toxicity and injuries caused by ionizing radiation; and Beitangning, a pioglitazone hydrochloride capsule to control blood glucose. Further, it offers Nuosen for acute upper digestive tract hemorrhage; Sailimai for the treatment of diarrhea; Apleek Transdermal Patch for contraception; Sidinuo for osteoporosis; Glucosamine hydrochloride tablets for osteoarthritis; Oulai, a compound sodium aescinate gel for local swelling; Oukai for the treatment of soft tissue swelling and venous edema; and Fengshiye for patients who have pains in bones, joints, and limbs. The company distributes and sells pharmaceutical drugs; and manufactures and sells biopharmaceutical products. Luye Pharma Group Ltd. was founded in 1994 and is headquartered in Yantai, the People's Republic of China.
2186 Stock 12 Month Forecast
Average Price Target
HK$4.32
▲(43.05% Upside)
Technical Analysis
CSPC Pharmaceutical Group
―
Zai Lab Ltd
―
Consun Pharmaceutical Group Ltd.
―
Lepu Biopharma Co. Ltd. Class H
―
CStone Pharmaceuticals
―
Options Prices
Currently, No data available
---